Around the Practice

Drs. Sara Hurvitz, Stefania Maraka, and Ruta Rao discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.

Expert panelists focus on a patient profile of metastatic urothelial cancer, discuss strategies and challenges for maintenance therapy, and comment on how recent clinical trial data presented at the 2022 ASCO Genitourinary Cancers Symposium may impact clinical practice for patients with the disease.

A panel of experts in stem cell transplant and cellular immunotherapy builds a lively discussion on current and emerging treatment options for the management of acute and chronic graft versus host disease.

Expert panelists center discussion around two patient cases to review use of newer anti-androgen deprivation therapy in the management of prostate cancer.

Experts center their discussion on patient profiles to highlight recent advances in the treatment of renal cell carcinoma and how they apply evidence from research into clinical practice to optimize patient outcomes.

A panel of experts provides a discussion on treatments for newly diagnosed transplant eligible, transplant ineligible, and relapsed multiple myeloma, and how recent clinical trial data presented at ASH 2021 can be applied to clinical practice.

Various healthcare professionals join to discuss the management of a patient diagnosed with HER2-positive breast cancer and consider how to best approach the patient with newer treatment strategies through her continuum of care.

Recommendations for introducing novel therapies into earlier lines of therapy for patients with transplant-eligible and transplant-ineligible multiple myeloma.

Expert panelists follow a patient case to discuss locally advanced and metastatic urothelial carcinoma with a focus on frontline and maintenance therapy.

A panel of experts discuss recent data results and updates happening within the HER2+ breast cancer treatment landscape.

A panel of experts reflect on how to treat patients with advanced renal cell carcinoma by reviewing clinical trial data and discussing patient cases.

Experts in prostate cancer discuss recent advances in the treatment of patients with metastatic castration-naive and metastatic castration-resistant prostate cancer and strategies for optimizing therapy.

A panel of experts review data from recent conferences and discuss core challenges in the treatment of patients with HER2+ metastatic breast cancer.

A panel of experts discusses current strategies used to stratify risk in patients with myelofibrosis and their preferences for sequencing therapy.

Recommendations for treating patients with steroid-refractory chronic GVHD based on evidence demonstrated by the REACH3 trial.

Shared insight on strategies for optimizing frontline therapy for patients with newly diagnosed multiple myeloma, including those with high-risk disease.

A panel of experts discuss strategies for optimizing first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma.

Experts provide their recommendations for navigating a large and continuously growing treatment landscape, selecting between regimens, and monitoring patients with transplant-ineligible multiple myeloma.

Experts in bladder cancer discuss best practices for treating patients with locally advanced and metastatic urothelial carcinoma.

Experts discuss best practices for treating patients with metastatic HER2+ breast cancer and consider optimal treatment options for patients with brain metastases and visceral disease.

Experts discuss best practices for treating patients with HER2+ breast cancer and suspected or actual brain metastases, as well as considerations for treatment sequencing and the identification and management of interstitial lung disease.

Experts in urology and nuclear medicine discuss the identification and management of biochemical recurrence in prostate cancer using 2 patient cases as examples.

Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.